Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.57 – $1.48
6% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $257.0M | $502.9M | $687.2M | $573.4M | $615.0M |
| Cost of revenue | $59.7M | $121.5M | $153.4M | $117.7M | $107.8M |
| Gross profit | $197.4M | $381.5M | $533.8M | $455.7M | $507.2M |
| Gross margin | 76.8% | 75.9% | 77.7% | 79.5% | 82.5% |
| R&D | $94.4M | $211.2M | $318.7M | $302.8M | $146.4M |
| Operating income | −$125.8M | −$119.0M | −$139.4M | −$445.8M | −$86.3M |
| EBITDA | −$116.8M | −$67.2M | −$76.8M | −$368.7M | −$48.5M |
| Net income | −$191.8M | −$236.7M | −$145.5M | −$433.5M | −$100.0M |
| Net margin | -74.6% | -47.1% | -21.2% | -75.6% | -16.3% |
| EPS (diluted) | -6.67 | -0.02 | -1.88 | -4.05 | -0.94 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $1.7B | $35.51 | $35.51–$35.51 | 1 |
| 2028 | $1.9B | $43.73 | $43.73–$43.73 | 1 |
| 2029 | $1.7B | $35.07 | $35.07–$35.07 | 1 |
| 2030 | $1.9B | $43.19 | $43.19–$43.19 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds LSB.
No tracked institution reports a position in LSB as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-10-04 | 1-for-10reverse |
No one on the platform has traded LSB yet.
| $28M |
| — |
| GMTXGemini Therapeutics, Inc. | $1.35 | +0.00% | $25M | — |
| IVCInvacare Corporation | $0.66 | +0.00% | $25M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$LSB Brilliant piece that captures LSB's situation perfectly. So if you want to update your understanding of LSB or get to know LSB better, this is essential reading. https://beyondspx.com/quote/LSB/analysis/lakeshore-biopharma-unlocking-value-through-proprietary-pika-technology-and-strategic-market-expansion-lsb
View on StockTwits ↗$LSB 08:04 on Sep. 12 2025 LakeShore Biopharma Receives Nasdaq Non-Compliance Notice #tradeideas
View on StockTwits ↗LakeShore Biopharma Receives Revised Proposal To Acquire Company $LSB https://stocktwits.com/news/equity/markets/lakeshore-biopharma-receives-revised-proposal-to-acquire-company/chs6JRRRdmm
View on StockTwits ↗LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside $LSB https://stocktwits.com/news/equity/markets/lakeshore-biopharma-got-an-acquisition-proposal-from-oceanpine-capital/chsO9ANRdXT
View on StockTwits ↗$QNTM $IBO $ALUR $GLTO $LSB $QNTM is targeting 3 big markets: • MS repair • Hangover relief • Alcohol detox Debt-free, $10.3M in assets, funded through 2027. Which catalyst hits first — Phase 2 MS trial, Unbuzzd sales growth, or REKVRY trial results? https://analyticainvestor.beehiiv.com/p/quantum-biopharma-taking-brain-health-in-bold-new-directions-803d3cda283ced6d
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.